Hollister Biosciences

CSE: HOLL | OTC: HSTRF | FWB: HOB

Canadian cannabis firm Hollister Biosciences entered into a definitive agreement to acquire Alphamind Brands, and closed the acquisition in April 2020. Alphamind are conducting R&D into psilocybin-based drug therapies, seeking to build an IP portfolio in the psychedelic medicine space.

[mstock id="3020"]

[mstock id="3021"]

Latest News

Hollister Biosciences Inc. Provides Update on Q3 2020 Performance

October 27, 2020

Hollister Biosciences 100% Owned Subsidiary Venom Extracts Achieves Initial $30 Million Revenue Milestone

October 6, 2020

Hollister Biosciences Retains Renmark Financial Communications Inc.

September 11, 2020

Hollister Biosciences Inc. Reports Second Quarter 2020 Results

August 24, 2020

Hollister Biosciences Inc. Closes $1.5 Million Private Placement Financing

August 11, 2020

Hollister Biosciences Inc. Announces Private Placement Financing of Up to $1.5 Million

July 2, 2020

Join our Newsletter

Get the latest Company updates delivered to straight to your inbox.

The VA, Psychedelics, and the Future of Mental Health: A Conversation with Shereef Elnahal, Former VA Under Secretary for HealthApril 14, 2025
Dr. Shereef Elnahal, former VA Under Secretary for health, discusses how he came to champion psychedelic research within the VA, the promising data in conditions like PTSD and substance use disorders, and the institutional groundwork needed to support the potential roll-out of these therapies at scale. He also shares his opinions on the balancing act between medicalisation and advocacy, and what a coordinated federal approach to psychedelics might, or should, look like.
Pα+ Psychedelic Bulletin #193: VA Secretary on Psychedelics; Preprint Challenges Replicability of Psilocybin’s Persistent Effects in Mice; Market Mayhem and Agency Shake-UpsApril 11, 2025
‘Everything’s On the Table’: VA Secretary Signals Openness to Psychedelics, But Concrete Plans Lacking • Drug Developers Caught Between Tariff Talk, Agency Shake-Ups, and Market Mayhem • Multi-Lab Preprint Study Challenges Replicability of Psilocybin’s Persistent Effects in Mice • Kwan Lab Links 5-HT2A Receptors and Pyramidal Tract to Psilocybin’s Lasting Effects in Mice • FDA Clears Nation’s First Whole-Mushroom Psilocybin Study • Terran vs. Compass Lawsuit Moves Forward as Court Rejects Dismissal • and more...
Psychedelic Policy Update: Medical Access, Industry Influence, and Voter Suppression Shape 2025 LandscapeApril 9, 2025
As New Mexico’s Medical Psilocybin Act Passes, Questions of Access, Provider Risk, and Industry Influence Loom • Arizona’s Oregon-Style Psilocybin Services Bill Gutted and Replaced by Compass Pathways’ Crystalline Polymorph Psilocybin Rescheduling Trigger Law • A Mixed Bag for Compass’ Other Trigger Law Bills • Idaho HJR 4 Passes, Preventing Voters from Legalising Psychoactive Drugs via Ballot Initiatives • Arizona Bill Carving Out $5M for Ibogaine Research Passes House, Working Way through Senate
BREAKING: New Mexico Passes Nation’s First Legislature-Driven Psilocybin Access ActApril 8, 2025
Yesterday, New Mexico Governor Michelle Lujan Grisham (D) signed SB 219, the Medical Psilocybin Act, which will establish the third state-legal psilocybin access system in the US. In simple terms, the Act creates a framework through which patients with qualifying conditions can access and use non-synthetic psilocybin through consultation with a licensed healthcare provider.
March 2025’s Psychedelic Policy Momentum: New Bills Filed Across the U.S. as Nearly 30 States Deliberate ReformsApril 7, 2025
With a half-dozen new states joining 2025's psychedelic policy reform push, there are now nearly thirty state legislatures mulling such proposals. Here, Noah Smith and Josh Hardman run through them state-by-state, bill-by-bill.

Hollister Biosciences

Latest News

Hollister Biosciences Inc. Provides Update on Q3 2020 Performance

Hollister Biosciences 100% Owned Subsidiary Venom Extracts Achieves Initial $30 Million Revenue Milestone

Hollister Biosciences Retains Renmark Financial Communications Inc.

Hollister Biosciences Inc. Reports Second Quarter 2020 Results

Hollister Biosciences Inc. Closes $1.5 Million Private Placement Financing

Hollister Biosciences Inc. Announces Private Placement Financing of Up to $1.5 Million

Join our Newsletter

Psychedelic Alpha

Quick Links

Newsletter

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights